You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.
The viral assay, developed with Sentinel Diagnostics, improves the ability to monitor viral loads in critical organ transplant populations for the clinical management of infection.
The PCR diagnostic device is a palm-size, single-use, disposable device that detects N. gonorrhoeae and determines if it's susceptible to an antibiotic.
The firm will use the proceeds for working capital and other general corporate purposes, with the potential to acquire or invest in complementary businesses, technologies, or assets.
The PCR viral load test runs on the Cobas 6800/8800 systems and has been calibrated to the World Health Organization International Standard, Roche said.
The tests use a range of different specimens including self-collected nasal swabs, bronchoalveolar lavage, sputum, and nasopharyngeal washes.
The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.
On an adjusted basis at constant exchange rates, revenues grew 19 percent year over year, in line with guidance provided by the company in early July.
Coastal Genomics owns the Ranger gel electrophoresis technology to collect specific DNA target sizes, with applications in noninvasive prenatal testing and oncology.
Results from the Phase II INSPIRE study showed that change in ctDNA from baseline, as gauged by customized assays, predicted response to pembrolizumab.
Zeesan's test may be used by any CLIA-certified high-complexity lab, while UCSD's test, which uses pooled samples, must be performed by the university.
The Clarigene SARS-CoV-2 IVD kit uses two viral RNA targets, nucleocapsid gene N and envelope gene E, which are specific to COVID-19, the firm said.
CEO Doug Bryant noted, in particular, what he expects will be a hunger for rapid protein-based antigen tests for the coronavirus that the market currently can't fill.
According to the company, the test has shown to be more sensitive and accurate than a COVID-19 anterior nasal swab test in the firm's EUA validation study.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
A SNP in the pan-SARS E gene has not affected patient results, but has raised concerns about the overall unavailability of commercial primer and probe information.
Lab firms are acquiring equipment and implementing approaches like pooled testing, but it remains unclear if this will be enough to meet a fall surge.
The test, which has Emergency Use Authorization from the US Food and Drug Administration, is designed to detect the SARS-CoV-2 ORF1ab, N, and E genes.
The firm saw $109 million in sales of its COVID-19-related products, including nearly $53 million in sales of its Lyra SARS-CoV-2 molecular diagnostic assay.
For the three months ended June 30, the genomic testing firm reported total revenues of $20.7 million.